| 4.62 0.05 (1.09%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.62 | 1-year : | 6.08 |
| Resists | First : | 4.81 | Second : | 5.21 |
| Pivot price | 4.73  |
|||
| Supports | First : | 4.17 | Second : | 3.47 |
| MAs | MA(5) : | 4.57 |
MA(20) : | 4.73 |
| MA(100) : | 4.48 |
MA(250) : | 3.99 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 20.5 |
D(3) : | 19.8 |
| RSI | RSI(14): 49.2 |
|||
| 52-week | High : | 5.21 | Low : | 3.05 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PYPD ] has closed above bottom band by 33.2%. Bollinger Bands are 18% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.76 - 4.78 | 4.78 - 4.8 |
| Low: | 4.45 - 4.47 | 4.47 - 4.49 |
| Close: | 4.58 - 4.62 | 4.62 - 4.65 |
PolyPid Ltd. is an advanced-stage biopharmaceutical company specializing in the development, manufacturing, and commercialization of therapeutic solutions. These solutions are based on its proprietary polymer-lipid encapsulation matrix (PLEX) platform, with the goal of addressing significant unmet medical needs. The company's leading product candidate, D-PLEX100, is currently undergoing Phase III clinical trials. It is being evaluated for its efficacy in preventing surgical site infections (SSIs) following both sternal (bone) and abdominal (soft tissue) procedures. Established in 2008, PolyPid Ltd. is headquartered in Petah Tikva, Israel.
Thu, 11 Jun 2026
PYPD Technical Analysis & Stock Price Forecast - Intellectia AI
Wed, 10 Jun 2026
PolyPid (PYPD) schedules July 15, 2026 meeting on director, auditor and option approvals - Stock Titan
Mon, 08 Jun 2026
When Can We Expect A Profit From PolyPid Ltd. (NASDAQ:PYPD)? - simplywall.st
Mon, 01 Jun 2026
PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀ - GlobeNewswire
Mon, 01 Jun 2026
PolyPid (Nasdaq: PYPD) files FDA NDA for D-PLEX100 infection drug - Stock Titan
Wed, 20 May 2026
PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 19 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 21.3 (%) |
| Held by Institutions | 33.6 (%) |
| Shares Short | 30 (K) |
| Shares Short P.Month | 44 (K) |
| EPS | -1.75 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.6 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -86.8 % |
| Return on Equity (ttm) | -366.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.65 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -28 (M) |
| Levered Free Cash Flow | -16 (M) |
| PE Ratio | -2.66 |
| PEG Ratio | 0 |
| Price to Book value | 7.69 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.18 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|